Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5997623 | 0.87 | SLC6A9 (0.51) | GPR139CYP2C9MEN1KMT2AKDM4E | |
| SCHEMBL5999559 | 0.82 | SLC6A9 (0.51) | MEN1KMT2A | |
| SCHEMBL5999076 | 0.81 | TACR1 (0.54) | EPHX2TMEM97SIGMAR1 | |
| SCHEMBL5999513 | 0.80 | NPC1 (0.52) | HPGDGPR139MEN1KMT2APOLB | |
| SCHEMBL5998832 | 0.80 | TACR1 (0.66) | GPR139 | |
| SCHEMBL5997782 | 0.77 | RAB9A (0.47) | HPGDHDAC1HDAC7MEN1KMT2A | |
| SCHEMBL5998526 | 0.76 | RAB9A (0.58) | HPGDCYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL6839111 | 0.75 | NPC1 (0.49) | MEN1KMT2APOLBHTT | |
| SCHEMBL23716319 | 0.74 | HPGD (0.59) | HPGDGPR139EPHX2CYP1A2CYP2C9 | |
| SCHEMBL5997936 | 0.72 | ALDH1A1 (0.51) | EPHX2CYP2C9CYP2C19KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082601-A1 | Anti-inflammatory compounds | SCOTT MALCOLM K (US) | 2004-04-29 | — | — | US | claimed |
| US-20030171585-A1 | Triphenylpropanamide compounds | SCOTT MALCOLM K (US) | 2003-09-11 | — | — | US | claimed |
| US-20020103217-A1 | Anti-inflammatory compounds | SCOTT MALCOLM K (US) | 2002-08-01 | — | — | US | claimed |
| US-6372779-B1 | ANTHRACENE DERIVATIVES WITH CARBAMOYL GROUPS, AMIDO GROUPS, UREA GROUPS AND SULFONAMIDE GROUPS | ORTHO PHARMACEUTICAL CORPORATION | 2002-04-16 | — | — | US | claimed |
| EP-0966430-A1 | ANTI-INFLAMMATORY COMPOUNDS | Ortho-Mcneil Pharmaceutical Corp. (US) | 1999-12-29 | — | — | EP | claimed |
| WO-1999033786-A1 | ANTI-INFLAMMATORY COMPOUNDS | ORTHO-MCNEIL PHARMACEUTICAL CORPORATION (US) | 1999-07-08 | — | — | WO | claimed |
| US-20030171585-A1 | Triphenylpropanamide compounds | SCOTT MALCOLM K (US) | 2003-09-11 | — | — | US | disclosed |
| US-6509369-B2 | Triphenylpropanamide compounds; useful in treating inflammations but which do not demonstrate side effects associated with other anti-inflammatory treatments such as glucocorticoids | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20020103217-A1 | Anti-inflammatory compounds | SCOTT MALCOLM K (US) | 2002-08-01 | — | — | US | disclosed |
| EP-0966430-B1 | ANTI-INFLAMMATORY COMPOUNDS | ORTHO MCNEIL PHARM INC (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6372779-B1 | ANTHRACENE DERIVATIVES WITH CARBAMOYL GROUPS, AMIDO GROUPS, UREA GROUPS AND SULFONAMIDE GROUPS | ORTHO PHARMACEUTICAL CORPORATION | 2002-04-16 | — | — | US | disclosed |
| EP-0966430-A1 | ANTI-INFLAMMATORY COMPOUNDS | Ortho-Mcneil Pharmaceutical Corp. (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999033786-A1 | ANTI-INFLAMMATORY COMPOUNDS | ORTHO-MCNEIL PHARMACEUTICAL CORPORATION (US) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082601-A1 | Anti-inflammatory compounds | TNF, PTGES, PTGES2 | HPGD 189/4885GPR139 2403/4885EPHX2 618/4885 |
| US-20030171585-A1 | Triphenylpropanamide compounds | PTGES, PTGES2, MPO | HPGD 544/4885GPR139 2815/4885EPHX2 1231/4885 |
| US-20020103217-A1 | Anti-inflammatory compounds | TNF, PTGES, PTGES2 | HPGD 189/4885GPR139 2403/4885EPHX2 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.